Compare GRMLW & EICC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GRMLW | EICC |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2022 | N/A |
| Metric | GRMLW | EICC |
|---|---|---|
| Price | $0.22 | $25.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.0K | ★ 45.9K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.96% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | N/A | ★ $51,224,692.00 |
| Revenue This Year | N/A | $39.61 |
| Revenue Next Year | N/A | $27.28 |
| P/E Ratio | ★ N/A | $45.32 |
| Revenue Growth | N/A | ★ 68.61 |
| 52 Week Low | $0.10 | $24.83 |
| 52 Week High | $0.37 | $25.84 |
| Indicator | GRMLW | EICC |
|---|---|---|
| Relative Strength Index (RSI) | 53.95 | 47.51 |
| Support Level | $0.13 | $24.99 |
| Resistance Level | $0.24 | $25.19 |
| Average True Range (ATR) | 0.05 | 0.03 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 42.98 | 94.44 |
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.